Far more than weight, and not all of it in one direction. A discovery study mapped GLP-1 use against 175 health outcomes across more than two million records [1]. Risk fell for neurocognitive, psychiatric and cardiometabolic conditions. Risk rose for gastrointestinal disorders, fainting, arthritic disorders, kidney stones, interstitial nephritis and drug-induced pancreatitis.
Most evidence about this drug class answers one question at a time. This one did the opposite, which makes it the widest view available. The width is why it is useful, and why it needs reading more carefully than a head-to-head comparison does.
How it was built
The study assembled a cohort of 215,970 people starting a GLP-1 in Veterans Affairs data. The comparison groups were 159,465 starting sulfonylureas, 117,989 starting DPP4 inhibitors and 258,614 starting SGLT2 inhibitors. A mixed control group held 536,068 and a usual-care group 1,203,097.
What went down
Against usual care, GLP-1 use was associated with reduced risk of substance use and psychotic disorders, seizures, and neurocognitive disorders including Alzheimer’s disease and dementia. Coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions also ran lower.
What went up
In the same analysis, GLP-1 use was associated with increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.
Two of those deserve a buyer’s attention. Hypotension and syncope mean fainting, which matters if you drive for a living or work at height. Kidney stones and interstitial nephritis are the kind of history a prescriber should ask about, and most sellers here publish nothing about what an intake covers.
What the single-outcome studies add
Two later analyses show what happens when one line of the atlas is examined on its own. The first compared semaglutide users against matched metformin users on COVID-19 and influenza severity, and found the advantage did not scale with dose [2].
A benefit that is the same at the lowest dose as at the highest is a different kind of claim from one that rises with exposure. What that costs to buy, and which rung of the ladder it implies, is the subject of the dose-response that was not there.
The second went the other way. In 19,770 matched pairs with diabetic neuropathy, GLP-1 users had fewer foot ulcers and about twice the rate of Charcot foot [3]. Amputations did not move. One outcome improved and a neighboring one worsened in the same population, which is the pattern in fewer ulcers and twice the Charcot.
Who these people were
The cohorts are US Veterans Affairs patients with diabetes. That population is older, overwhelmingly male, and under continuous medical follow-up. Almost nothing about it resembles the person buying compounded semaglutide through a website.
The comparison groups matter too. Everyone here was taking something for diabetes, so the contrast is GLP-1 against other diabetes drugs rather than against nothing. That is a fairer comparison than most observational work manages, and it is a different question from the one a first-time buyer is asking. The same caution about very large observational effects applies in a 77% mortality reduction nobody can use.
What survives into a purchase decision
Not much directly, and that is the honest answer. What it establishes is the shape of the trade: broad benefit across several organ systems, alongside a real and specific list of things that get worse. Neither half is visible on a product page.
The practical version does not change. Know what you are buying, know what it costs when the dose rises, and know how to reach someone. The price distribution covers the first, the dose-pricing census covers the second, and the ranked board shows which sellers publish enough to answer the third.
Corpus figures on this site are computed at build time, most recently read September 2026. The outcome associations above are cited and are not this site’s own.